



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dasseux *et al.* Confirmation No.: 4097
Serial No.: 10/801,897 Art Unit: 1654
Filed: March 15, 2004 Examiner: Jeffrey E. Russel
For: APOLIPOPROTEIN A-I Attorney Docket No.: 9196-032-999
AGONISTS AND THEIR USE TO (PC20702C)
TREAT DYSLIPIDEMIC
DISORDERS

REPLY AND AMENDMENT AFTER FINAL REJECTION (37 CFR § 1.116)

MAIL STOP AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Okay to
enter
JER
9-26-2006

The enclosed Reply and Amendment under 37 C.F.R. § 1.116 is in reply to the Office Action dated April 10, 2006, for the above-identified patent application. Applicants respectfully request that the Examiner enter the present amendment after final rejection, which will resolve all outstanding rejections and place the application in condition for allowance. Pursuant to 37 CFR 1.116(b)(1), Applicants are canceling certain claims. The period for response to this Office Action has been extended to September 10, 2006, pursuant to Applicants' Petition for Extension of Time filed herewith.

Amendments to the Specification start on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks begin on page 8 of this paper.

Also enclosed are:

Petition for Extension of Time from July 10, 2006, to and including September 10, 2006, for responding to the Office Action;
Substitute Paper Copy of Sequence Listing;
Sequence Listing Certificate; and
Notice of Appeal